Serum decoy receptor 3, a potential new biomarker for sepsis

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 744-748

  Hou, Yan Qiang ^a   Xu, Ping ^a   Zhang, Mei ^b   Han, Deping ^c   Peng, Liang ^a   Liang, Dong Yu ^a   Yang, Shanmin ^b   Zhang, Zhenhuan ^b   Hong, Jinsheng ^c   Lou, Xiao Li ^a   Zhang, Lurong ^b   Kim, Sunghee ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d BioPowerTech   (United States)

Author keywords

Biomarkers; DcR3; Diagnosis; Sepsis; SIRS

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DECOY RECEPTOR 3; INTERLEUKIN 6; PROCALCITONIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; APACHE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; ROC CURVE; SEPSIS;

EID: 84862808988     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.007     Document Type: Article

References (43)

1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655. American College of Chest Physicians/Society of Critical Care Medicine.
2. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 2005, 351:17-29.
4. Carlet J. Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 1999, 13:483-494. xi.
5. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
6. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
7. Bozza F.A., Salluh J.I., Japiassu A.M., Soares M., Assis E.F., Gomes R.N., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11:R49.
8. Oconnor E., Venkatesh B., Mashongonyika C., Lipman J., Hall J., Thomas P. Serum procalcitonin and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage. Anaesth Intensive Care 2004, 32:465-470.
9. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
10. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15.
11. Vincent J.L. Procalcitonin: THE marker of sepsis?. Crit Care Med 2000, 28:1226-1228.
12. Ruokonen E., Nousiainen T., Pulkki K., Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999, 18:283-285.
13. Ugarte H., Silva E., Mercan D., De Mendonca A., Vincent J.L. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999, 27:498-504.
14. Tang B.M., Eslick G.D., Craig J.C., McLean A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007, 7:210-217.
15. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492.
16. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
17. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999, 274:13733-13736.
18. Lin W.W., Hsieh S.L. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011, 81:838-847.
19. Kim S., Fotiadu A., Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005, 115:286-294.
20. Kim S., McAuliffe W.J., Zaritskaya L.S., Moore P.A., Zhang L., Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004, 72:89-93.
21. Bamias G., Kaltsa G., Siakavellas S.I., Papaxoinis K., Zampeli E., Michopoulos S., et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010, 137:242-249.
22. Lee C.S., Hu C.Y., Tsai H.F., Wu C.S., Hsieh S.L., Liu L.C., et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008, 151:383-390.
23. Chen C.C., Yang Y.H., Lin Y.T., Hsieh S.L., Chiang B.L. Soluble decoy receptor 3: increased levels in atopic patients. J Allergy Clin Immunol 2004, 114:195-197.
24. Bamias G., Siakavellas S.I., Stamatelopoulos K.S., Chryssochoou E., Papamichael C., Sfikakis P.P. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 2008, 129:249-255.
25. Ka S.M., Sytwu H.K., Chang D.M., Hsieh S.L., Tsai P.Y., Chen A. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol 2007, 18:2473-2485.
26. Chen C.Y., Yang K.Y., Chen M.Y., Chen H.Y., Lin M.T., Lee Y.C., et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 2009, 180:751-760.
27. Chen J., Zhang L., Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004, 285:63-70.
28. Bell K., Wattie M., Byth K., Silvestrini R., Clark P., Stachowski E., et al. Procalcitonin: a marker of bacteraemia in SIRS. Anaesth Intensive Care 2003, 31:629-636.
29. Balc I.C., Sungurtekin H., Gurses E., Sungurtekin U., Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003, 7:85-90.
30. Selberg O., Hecker H., Martin M., Klos A., Bautsch W., Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000, 28:2793-2798.
31. von Lilienfeld-Toal M., Dietrich M.P., Glasmacher A., Lehmann L., Breig P., Hahn C., et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004, 23:539-544.
32. Muller B., Becker K.L., Schachinger H., Rickenbacher P.R., Huber P.R., Zimmerli W., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
33. Suprin E., Camus C., Gacouin A., Le Tulzo Y., Lavoue S., Feuillu A., et al. Procalcitonin: a valuable indicator of infection in a medical ICU?. Intensive Care Med 2000, 26:1232-1238.
34. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
35. Kumar A.T., Sudhir U., Punith K., Kumar R., Ravi Kumar V.N., Rao M.Y. Cytokine profile in elderly patients with sepsis. Indian J Crit Care Med 2009, 13:74-78.
36. Vincent J.L., Sun Q., Dubois M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093.
37. Pugin J. Biomarkers of sepsis: is procalcitonin ready for prime time?. Intensive Care Med 2002, 28:1203-1204.
38. Giamarellos-Bourboulis E.J., Mega A., Grecka P., Scarpa N., Koratzanis G., Thomopoulos G., et al. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. Intensive Care Med 2002, 28:1351-1356.
39. Ward P.A. Sepsis, apoptosis and complement. Biochem Pharmacol 2008, 76:1383-1388.
40. Yang C.R., Hsieh S.L., Ho F.M., Lin W.W. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005, 174:1647-1656.
41. Funke B., Autschbach F., Kim S., Lasitschka F., Strauch U., Rogler G., et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009, 58:483-491.
42. Chen P.H., Yang C.R. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441-8449.
43. Kim S., Kotoula V., Hytiroglou P., Zardavas D., Zhang L. Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig Liver Dis 2009, 41:591-598.